1. First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. Issue 22 (18th August 2020) Authors: Geva, Ravit; Voskoboynik, Mark; Dobrenkov, Konstantin; Mayawala, Kapil; Gwo, Jennifer; Wnek, Richard; Chartash, Elliot; Long, Georgina V. Journal: Cancer Issue: Volume 126:Issue 22(2020) Page Start: 4926 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗